There are 2 clinical trials
Prospective multi-center surveillance study on the prevalence of azole-resistant Aspergillus spp. in clinical isolates of patients with pulmonary colonization or invasive infections in Switzerland
These mutations, including TR34/L98H and TR46/Y121F/T289A have been identified in the environment and have been demonstrated to cause resistance to azole fungicides used in agriculture. --- L98H --- --- Y121F ---
Description: Distribution of antifungal susceptibility profile of all tracheal and urinary samples in clinical Aspergillus isolates
Measure: Azole-resistance in Aspergillus (A.) fumigatus Time: start of study until end of study (July 2017 until December 2018)A standard treatment protocol for invasive aspergillosis (IA) will be implemented in several academic hematology centers in the Netherlands in which a diagnostic test demonstrating azole resistance by multiplex real-time polymerase chain reaction will guide the choice of appropriate antifungal treatment. Objectives: 1. Improve the outcome of patients infected with azole resistant A. fumigatus by the early detection of Resistance Associated Mutations (RAMs) and with this the earlier initiation of the most appropriate therapy. 2. Monitor the prevalence of invasive aspergillosis due to strains carrying the TR34/L98H or the TR46/T289A/Y121F resistance associated mutations in the Netherlands.
2. Monitor the prevalence of invasive aspergillosis due to strains carrying the TR34/L98H or the TR46/T289A/Y121F resistance associated mutations in the Netherlands. --- L98H --- --- Y121F ---
Description: Incidence of antifungal treatment failure in patients with the presence of RAM detected by the AsperGenius® resistance PCR. This incidence will be compared with a fixed failure rate set at 75%, based on the observed treatment failure in patients treated with voriconazole that were shown to carry azole resistant A. fumigatus.
Measure: Incidence of antifungal treatment failure Time: 12 weeksDescription: This will be compared with a fixed mortality of 50%.
Measure: Demonstrate that early detection of azole resistance reduces the overall mortality. Time: 6 weeksDescription: Posaconazole step down therapy will be considered effective if <35% of the patients treated with posaconazole oral monotherapy show progression of their invasive aspergillosis after documented response after at least 14 days of IV antifungal therapy.
Measure: Demonstrate that a step down to oral posaconazole is a reasonable treatment option in patients that have responded to at least 2 weeks of IV antifungal therapy. Time: 12 weeksDescription: A group that received appropriate antifungal therapy soon will be compared with a group that received treatment late.
Measure: Comparison of antifungal treatment failure in patients with the presence of RAM. Time: 24 weeks